Patents Assigned to Hormos Medical Corporation
-
Patent number: 9855224Abstract: This invention relates to a method for enhancing the bioavailability of a therapeutically active compound of the formula (I) or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof, wherein said compound is administered orally to the individual in connection with the intake of food.Type: GrantFiled: December 16, 2015Date of Patent: January 2, 2018Assignee: HORMOS MEDICAL CORPORATIONInventor: Markku Anttila
-
Patent number: 8642079Abstract: This invention relates to a solid drug formulation comprising granulates containing a therapeutically active compound of the formula (I) or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof, in combination with one or more intra-granular excipients.Type: GrantFiled: February 23, 2004Date of Patent: February 4, 2014Assignee: Hormos Medical CorporationInventors: Veli-Matti Lehtola, Kaija Halonen
-
Publication number: 20130345313Abstract: This invention concerns a method for treatment or prevention of lower urinary tract symptoms with or without pelvic pain in an individual, said method comprising administering to the individual an effective amount of a selective estrogen receptor modulator, or an isomer, isomer mixture or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: August 19, 2013Publication date: December 26, 2013Applicant: Hormos Medical CorporationInventors: Risto Santti, Tomi Streng
-
Publication number: 20120270952Abstract: This invention relates to a method for enhancing the bioavailability of a therapeutically active compound of the formula (I) or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof, wherein said compound is administered orally to the individual in connection with the intake of food.Type: ApplicationFiled: July 6, 2012Publication date: October 25, 2012Applicant: Hormos Medical CorporationInventor: Markku ANTTILA
-
Patent number: 8236861Abstract: This invention relates to a method for enhancing the bioavailability of a therapeutically active compound of the formula (I) or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof, wherein said compound is administered orally to the individual in connection with the intake of food.Type: GrantFiled: February 13, 2004Date of Patent: August 7, 2012Assignee: Hormos Medical CorporationInventor: Markku Anttila
-
Patent number: 7528166Abstract: Novel phenolic esters of lignans, and pharmaceutical compositions, dietary supplements, and food products containing these esters.Type: GrantFiled: January 21, 2003Date of Patent: May 5, 2009Assignee: Hormos Medical CorporationInventors: Patrik Eklund, Mervi Hiilovaara-Teijo, Arja Kalapudas, Lauri Kangas, Anna Lindholm, Rainer Sjohölm, Marja Södervall, Mikko Unkila
-
Publication number: 20060293294Abstract: This invention relates to a method for the treatment or prevention of androgen deficiency in a male individual by administering to the individual an effective amount of a selective estrogen receptor modulator, or an isomer, isomer mixture, metabolite or a pharmaceutically acceptable salt thereof. Furthermore, the invention concerns methods for the treatment or prevention of diseases or disorders caused by androgen deficiency.Type: ApplicationFiled: July 18, 2005Publication date: December 28, 2006Applicant: HORMOS MEDICAL CORPORATIONInventors: Taru Blom, Janne Komi, Risto Lammintausta
-
Patent number: 7153982Abstract: A method for the production of hydroxymatairesinol or a hydroxymatairesinol complex from wood, including the steps of a) extracting finely divided wood material with a polar solvent, b) optionally concentrating the extract by separating at least part of the solvent, c) adding to the extract an agent able to form a complex with hydroxymatairesinol, d) precipitating the hydroxymatairesinol complex, and optionally e) releasing the hydroxymatairesinol from the complex.Type: GrantFiled: November 15, 2002Date of Patent: December 26, 2006Assignee: Hormos Medical CorporationInventors: Seppo Parhi, Mervi Puska, Arja Kalapudas, Helena Korte, Petri Hukka
-
Publication number: 20060154870Abstract: This invention concerns a method for treating or preventing a disease or disorder related to excessive formation of vascular tissue or blood vessels in a patient, said method comprising administering to said patient an agent affecting the NPY Y2 receptor.Type: ApplicationFiled: March 10, 2006Publication date: July 13, 2006Applicant: Hormos Medical CorporationInventors: Markku Koulu, Jukka Tuohimaa, Ullamari Pesonen, Jaana Kallio, Matti Karvonen
-
Patent number: 7049449Abstract: A method for the preparation of lariciresinol, cyclolariciresinol or secoisolariciresinol, which method includes the steps of a) reducing hydroxymatairesinol to give 7-hydroxy-secoisolariciresinol, and b) subjecting the 7-hydroxy-secoisolariciresinol obtained in step a) to i) cyclization to give lariciresinol, or ii) cyclization to give cyclolariciresinol, or iii) catalytic hydrogenolysis to give secoisolariciresinol.Type: GrantFiled: January 7, 2003Date of Patent: May 23, 2006Assignee: Hormos Medical CorporationInventors: Rainer Sjöholm, Patrik Eklund, Jyri-Pekka Mikkola
-
Patent number: 6984665Abstract: This invention relates to a method for inhibition of skin atrophy, or epithelial or mucosal atrophy in women, or to a method for treatment or prevention of symptoms related to said atrophy, said method comprising administering to the woman an effective amount of the compound of formula (I) or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof.Type: GrantFiled: June 6, 2002Date of Patent: January 10, 2006Assignee: Hormos Medical CorporationInventors: Taru Blom, Paula Grönroos, Kaija Halonen, Pirkko Härkönen
-
Publication number: 20050272825Abstract: This invention relates to a method for inhibition of skin atrophy, or epithelial or mucosal atrophy in women, or to a method for treatment or prevention of symptoms related to said atrophy, said method comprising administering to the woman an effective amount of the compound of formula (I) or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof.Type: ApplicationFiled: August 11, 2005Publication date: December 8, 2005Applicant: Hormos Medical CorporationInventors: Taru Blom, Paula Gronroos, Kaija Halonen, Pirkko Harkonen
-
Publication number: 20050187302Abstract: This invention relates to a method for the treatment or prevention of osteoporosis in an individual suffering from increased bone turnover, said method comprising administering to said individual an effective amount of a therapeutically active compound, which is a selective estrogen receptor modulator of the triphenylalkene or triphenylalkane structure.Type: ApplicationFiled: February 23, 2004Publication date: August 25, 2005Applicant: Hormos Medical CorporationInventors: Taru Blom, Lauri Kangas, Risto Lammintausta
-
Publication number: 20050187301Abstract: This invention relates to a solid drug formulation comprising granulates containing a therapeutically active compound of the formula (I) or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof, in combination with one or more intra-granular excipients.Type: ApplicationFiled: February 23, 2004Publication date: August 25, 2005Applicant: Hormos Medical CorporationInventors: Veli-Matti Lehtola, Kaija Halonen
-
Publication number: 20050182143Abstract: This invention relates to a method for enhancing the bioavailability of a therapeutically active compound of the formula (I) or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof, wherein said compound is administered orally to the individual in connection with the intake of food.Type: ApplicationFiled: February 13, 2004Publication date: August 18, 2005Applicant: Hormos Medical CorporationInventor: Markku Anttila
-
Publication number: 20050107327Abstract: This invention relates to method for reducing the overproduction of neuropeptide Y (NPY) in an individual, said method being aimed to modulate an overactive NPY system in said individual. The overproduction is either counteracted by administering an antagonist, or in case the individual has a polymorphism comprising the substitution of the position 7 leucine for proline in the signal peptide part of the preproNPY, said individual is subjected to a method aimed to reduce or prevent expression of the mutated allele causing said polymorphism.Type: ApplicationFiled: October 22, 2004Publication date: May 19, 2005Applicant: HORMOS MEDICAL CORPORATIONInventors: Markku Koulu, Matti Karvonen, Ullamari Pesonen, Matti Uusitupa, Jaana Kallio
-
Patent number: 6891070Abstract: A new method for the preparation of a selective estrogen receptor modulator and its isomers. Also disclosed is the preparation of new intermediates and their use in the preparation of the selective estrogen receptor modulator.Type: GrantFiled: March 21, 2002Date of Patent: May 10, 2005Assignee: Hormos Medical CorporationInventors: Arja Kalapudas, Marja Södervall
-
Publication number: 20050080299Abstract: A method for the preparation of matairesinol from hydroxymatairesinol, either by (i) catalytic hydrogenolysis of the hydroxy group in 7-position of hydroxymatairesinol, where the reaction is carried out in a suitable solvent as a pressurized hydrogenolysis, or (ii) reduction of hydroxymatairesinol, where the reduction is carried out as a hydrogen transfer reaction from a hydrogen donor in the presence of a catalyst.Type: ApplicationFiled: January 2, 2003Publication date: April 14, 2005Applicant: Hormos Medical CorporationInventors: Rainer Sjoholm, Patrik Eklund, Jyri Mikkola, Reko Lehtila, Marja Sodervale, Arja Kalapudas
-
Publication number: 20030036566Abstract: This invention relates to a method for inhibition of skin atrophy, or epithelial or mucosal atrophy in women, or to a method for treatment or prevention of symptoms related to said atrophy, said method comprising administering to the woman an effective amount of the compound of formula (I) 1Type: ApplicationFiled: June 6, 2002Publication date: February 20, 2003Applicant: Hormos Medical CorporationInventors: Taru Blom, Paula Gronroos, Kaija Halonen, Pirkko Harkonen